Hostname: page-component-74656f9884-skzmx Total loading time: 0 Render date: 2026-11-06T07:35:04.545Z Has data issue: false hasContentIssue false
  • English
  • Français

Crystal structure and X-ray powder diffraction data for two solid-state forms of topiroxostat

Published online by Cambridge University Press:  30 August 2022

Dier Shi ,
Jiyong Liu  and
Xiurong Hu Open the ORCID record for Xiurong Hu [Opens in a new window]
Dier Shi
Affiliation:
Department of Chemistry, Zhejiang University, Hangzhou 310027, PR China
Jiyong Liu
Affiliation:
Department of Chemistry, Zhejiang University, Hangzhou 310027, PR China
Xiurong Hu*
Affiliation:
Department of Chemistry, Zhejiang University, Hangzhou 310027, PR China
*
a)Author to whom correspondence should be addressed. Electronic mail: huxiurong@zju.edu.cn

Abstract

X-ray powder diffraction data, unit-cell parameters, and space group for the topiroxostat form II, C13H8N6, are reported [a = 7.344(9) Å, b = 12.946(7) Å, c = 12.133(5) Å, β = 96.99(3)°, V = 1145.2(4) Å3, Z = 4, and space group P21/c]. The topiroxostat monohydrate, C13H8N6·H2O, crystallized in a triclinic system and unit-cell parameters are also reported [a = 7.422(9) Å, b = 8.552(1) Å, c = 11.193(5) Å, α = 74.85(1)°, β = 81.17(1)°, γ = 66.29(1)°, V = 627.0(6) Å3, Z = 2, and space group P-1]. In each case, all measured lines were indexed and are consistent with the corresponding space group. The single-crystal data of two solid-state forms of topiroxostat are also reported, respectively [a = 7.346(2) Å, b = 12.955(2) Å, c = 12.130(7) Å, β = 96.91(6)°, V = 1146.1(3) Å3, Z = 4, and space group P21/c] and [a = 7.418(6) Å, b = 8.532(8) Å, c = 11.183(9) Å, α = 74.807(1) °, β = 81.13(1)°, γ = 66.32(1) °, V = 624.7(6) Å3, Z = 2, and space group P-1]. The experimental powder diffraction pattern has been well matched with the simulated pattern derived from the single-crystal data.

Keywords

X-ray powder diffraction datatopiroxostatsolid-state form

Information

Type
New Diffraction Data
Information
Powder Diffraction , Volume 37 , Issue 3 , September 2022 , pp. 166 - 170
Check for updates
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press on behalf of International Centre for Diffraction Data

I. INTRODUCTION

Topiroxostat (4-(5-(pyridine-4-yl)-1H-1,2,4-triazole-3-yl)pyridine-2-carbonitrile) is a selective xanthine oxidoreductase inhibitor, which is effective in decreasing urinary albumin excretion and reducing the level of serum urate in the human body (Hosoya et al., Reference Hosoya, Ohno, Nomura, Hisatome, Uchida, Fujimori, Yamamoto and Hara2014). Thus, topiroxostat (TOPI) was approved in Japan in June 2013 for the treatment of gout and hyperuricemia (Hosoya et al., Reference Hosoya, Sasaki, Hashimoto, Sakamoto and Ohashi2016). The chemical structure of topiroxostat is shown in Figure 1. As is known that more than half of the pharmaceutical compounds exhibit solid-state polymorphism, and is of great importance as different crystal forms of the drug can show different stability, solubility, dissolution rate and bioavailability, especially for poorly soluble drugs. TOPI has been reported that there are five different crystal forms, such as form I, form II, form III, monohydrate and form A (Lee et al., Reference Lee, Erdemir and Myerson2011; Iwabuchi et al., Reference Iwabuchi, Miyata, Sato, Uda, Kandou, Inoue and Nakano2014), but their crystal structures have not been reported yet.

Figure 1.

Chemical structure of 4-(5-(pyridine-4-yl)-1H-1,2,4-triazole-3-yl)pyridine-2-carbonitrile.

We have inspected the Cambridge Structural Database (Groom et al., Reference Groom, Bruno, Lightfoot and Ward2016) and the PDF4 + database (Gates-Rector and Blanton, Reference Gates-Rector and Blanton2019) and have not found any entries for the topiroxostat form II (TOPI-II) and the topiroxostat monohydrate (TOPI-H2O) in the mentioned databases. Therefore, we have decided to characterize these compounds by X-ray powder diffraction and X-ray single-crystal diffraction techniques.

II. EXPERIMENTAL

A. Sample preparations

The sample was supplied by Zhejiang Jingxin Pharmaceutical Co., Ltd (purity >99.9%) and used without further purification. Dissolving topiroxostat (400 mg) in anhydrous ethanol (250 ml) and ethanol–water (300 ml, 9:1 v/v), respectively, at reflux temperature and slow cooling of the solutions yielded crystals of TOPI-II and TOPI-H2O. Then, the crystals were dried, smashed and mounted on a flat zero-background plate.

B. Powder diffraction data collection

X-ray powder diffraction data were collected at room temperature with a SmartLab diffractometer with parafocusing Bragg-Brentano geometry using a Cu Kα radiation (λ = 1.5418 Å) and operated at 40 kV and 180 mA. The D/tex Ultra 250 detector was employed to collect XRD data over the 2θ range from 3° to 50° with a step size of 0.02° and a counting time of 1.2 s step−1. The software package MDI-Jade version 7.5 (Materials Data Inc., USA) was used to smooth the data, fit the background, strip off the Kα2 component and obtain the peak positions and intensities (Tables I and II). The Kα1was used in converting observed 2θ to d-spacing.

TABLE I.

X-ray powder diffraction data of TOPI-II.

TABLE II.

X-ray powder diffraction data of TOPI-H2O.

C. Single-crystal diffraction data collection

X-ray single-crystal diffraction data were collected at room temperature with a Bruker D8 Venture diffractometer with Mo Kα radiation (λ = 0.71073 Å) for cell determination and subsequent data collection. Data reduction was performed by APEX3 software and multi-scan absorption correction was applied. Using Olex2 (Dolomanov et al., Reference Dolomanov, Bourhis, Gildea, Howard and Puschmann2009), the structures were solved with the ShelXT (Sheldrick, Reference Sheldrick2015a) structure solution program using intrinsic-phasing and refined with the ShelXL (Sheldrick, Reference Sheldrick2015b) refinement package using Least Squares minimization.

III. RESULTS AND DISCUSSION

Indexing of the experimental X-ray diffraction patterns and unit-cell refinements were done using MDI-Jade (Materials Data Inc., 2002). The cell refinement results confirmed that TOPI-II is monoclinic with the space group P21/c and unit-cell parameters: a = 7.344(9) Å, b = 12.946(7) Å, c = 12.133(5) Å, β = 96.99(3)°, unit-cell volume V = 1145.2(4) Å3, Z = 4. The figure of merit is F 30 = 184.8(0.0053,30) (Smith and Snyder, Reference Smith and Snyder1979). TOPI-H2O is also triclinic with the space group P-1 and unit-cell parameters: a = 7.422(9) Å, b = 8.552(1) Å, c = 11.193(5) Å, α = 74.85(1)°, β = 81.17(1)°, γ = 66.29(1)°, unit-cell volume V = 627.0(6) Å3 and Z = 2. The figure of merit is F 30 = 72.5 (0.013,30) (Smith and Snyder, Reference Smith and Snyder1979). The values of 2θ obs, d obs, I obs, h, k, l, 2θ cal, d cal, I cal and Δ2θ are listed in Tables I and II. Because the morphology of TOPI-II and TOPI-H2O was plate crystals with preferred orientations, there is a minor difference in the relative intensities of the diffraction peaks between the experimental X-ray diffraction patterns and the calculated XRD patterns.

Based on the single-crystal data, the structures of TOPI-II and TOPI-H2O were solved and refined. The detailed crystallographic information is summarized in Supplementary Tables SI–SIII, and the asymmetric units of both forms with the corresponding atom labeling scheme are illustrated in Figure 2. In the crystal structure of TOPI-II, there is one topiroxostat molecule in the asymmetric unit, which is connected by hydrogen bond N2–H4⋯N6i [symmetric code: (i) 2−x, 1/2+y, 3/2−z] to form an infinite “zigzag” chain along the b-axis. The asymmetric unit of TOPI-H2O contains a topiroxostat molecule and an H2O molecule. In the crystal structure, the H2O molecule was involved in hydrogen bonding (O1–H1B⋯N2ii, O1–H1A⋯N6iii, N4–H4⋯O1, [symmetric code: (ii) x, y, –1 + z; (iii) −1 + x, 1 + y, z]) with the topiroxostat molecule forming hydrogen two-dimensional hydrogen-bond networks.

Figure 2.

Asymmetric unit of TOPI-II (a) and TOPI-H2O (b) shown in the thermal ellipsoid model with 50% probability. The crystal packing of TOPI-II (c) and TOPI-H2O (d) in the unit cell.

In addition, there are good agreements between the experimental powder diffraction pattern and the simulated pattern derived from the single-crystal data (Figures 3 and 4). The deviations of the unit-cell parameters and unit-cell volume of TOPI-II were between 0.07% and 0.08%. The deviations of the unit-cell parameters and unit-cell volume of TOPI-H2O were between 0.23% and 0.37%.

Figure 3.

X-ray powder diffraction pattern (black line) and the simulated pattern of the crystal structure (red line) of TOPI-II.

Figure 4.

X-ray powder diffraction pattern (black line) and the simulated pattern of the crystal structure (red line) of TOPI-H2O.

SUPPLEMENTARY MATERIAL

The supplementary material for this article can be found at https://doi.org/10.1017/S088571562200029X.

FUNDING INFORMATION

This work was financially supported from Zhejiang University Experimental Technology Research (SYB202103).

References

Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., and Puschmann, H. (2009). “OLEX2: a complete structure solution, refinement and analysis program,” J. Appl. Crystallogr. 42, 339–341.CrossRefGoogle Scholar
Gates-Rector, S. and Blanton, T. (2019). “The powder diffraction file: a quality materials characterization database,” Powd. Diffr. 34, 352–360.CrossRefGoogle Scholar
Groom, C. R., Bruno, I. J., Lightfoot, M. P., and Ward, S. C. (2016). “The Cambridge structural database,” Acta Crystallogr. 72, 171–179.Google ScholarPubMed
Hosoya, T., Ohno, I., Nomura, S., Hisatome, I., Uchida, S., Fujimori, S., Yamamoto, T., and Hara, S. (2014). “Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout,” Clin. Exp. Nephrol. 18, 876–884.CrossRefGoogle ScholarPubMed
Hosoya, T., Sasaki, T., Hashimoto, H., Sakamoto, R., and Ohashi, T. (2016). “Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study,” J. Clin. Phar. Ther. 41, 298–305.CrossRefGoogle ScholarPubMed
Iwabuchi, Y., Miyata, S., Sato, T., Uda, J., Kandou, T., Inoue, T., and Nakano, H. (2014). “4-(5-(pyridine-4-yl)-1H-1,2,4-triazole-3-yl)pyridine-2-carbonitrile crystalline polymorph and production method therefor,” the Patent Corporate Body Aruga Patent Office WO2014017515A.Google Scholar
Lee, A. Y., Erdemir, D., and Myerson, A. S. (2011). “Crystal polymorphism in chemical process development,” Annu. Rev. Chem. Biomol. Eng. 2, 259–280.CrossRefGoogle ScholarPubMed
Materials Data Inc. (MDI) and the International Centre for Diffraction Data (ICDD). (2002). Jade 7.5 XRD Pattern Processing Software.Google Scholar
Sheldrick, G. M. (2015a). “SHELXT - integrated space-group and crystal-structure determination,” Acta Crystallogr. A71, 3–8.Google Scholar
Sheldrick, G. M. (2015b). “Crystal structure refinement with SHELXL,” Acta Crystallogr. C71, 3–8.Google Scholar
Smith, G. S. and Snyder, R. L. (1979). “FN: a criterion for rating powder diffraction patterns and evaluating the reliability of powder-pattern indexing,” J. Appl. Crystallogr. 12, 60–65.CrossRefGoogle Scholar
Figure 0

Figure 1. Chemical structure of 4-(5-(pyridine-4-yl)-1H-1,2,4-triazole-3-yl)pyridine-2-carbonitrile.

Figure 1

TABLE I. X-ray powder diffraction data of TOPI-II.

Figure 2

TABLE II. X-ray powder diffraction data of TOPI-H2O.

Figure 3

Figure 2. Asymmetric unit of TOPI-II (a) and TOPI-H2O (b) shown in the thermal ellipsoid model with 50% probability. The crystal packing of TOPI-II (c) and TOPI-H2O (d) in the unit cell.

Figure 4

Figure 3. X-ray powder diffraction pattern (black line) and the simulated pattern of the crystal structure (red line) of TOPI-II.

Figure 5

Figure 4. X-ray powder diffraction pattern (black line) and the simulated pattern of the crystal structure (red line) of TOPI-H2O.

Supplementary material: File

Shi et al. supplementary material

Shi et al. supplementary material

Download Shi et al. supplementary material(File)
File 20.4 KB